Explore facts and recommendations for pharmacological treatments for obesity.
Learn more about the Wegovy™ Dosing Guidelines. Wegovy™ should be initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached.
Explore a snapshot of why medication is a powerful tool in obesity management.
Review outcomes and warnings for weight-loss medications currently approved by the FDA.
Researching other disease states?
Find medical information and ask questions about diabetes, hemophilia and more at Novo Nordisk Medical.
Learn more about Wegovy’s™ STEP 1-4 clinical trials. These trials were built to evaluate its safety and efficacy for weight management in adult patients living with obesity and weight-related comorbidities.
See the results of a 68-week trial comparing weight loss while receiving Wegovy™ or placebo in 1961 adults with obesity or overweight.
View the findings of a 68-week trial comparing Wegovy™ vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.
See the outcomes of a 68-week trial comparing Wegovy™ vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.
We're ready to help.
Speak with a Novo Nordisk medical information specialist for real-time answers to your questions about obesity research and treatments.
Review the findings of a 68-week trial comparing sustained weight management in adults with obesity or overweight and at least 1 weight-related comorbidity while receiving Wegovy™ or placebo.
Questions about obesity research or other disease states?
Speak to a live medical information specialist or submit a question via our web form.
For other therapeutic areas, visit our Novo Nordisk Medical website.